Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Next AdvaMed Chief Is BIO Exec Scott Whitaker

This article was originally published in The Gray Sheet

Executive Summary

Whitaker, appointed as the next CEO of AdvaMed, currently runs day-to-day operations at the Biotechnology Innovation Organization and has held high-level posts at HHS. Among his accomplishments, Whitaker led the legislative office at HHS when the first device user fee bill was passed in 2002.

You may also be interested in...

Q&A With Scott Whitaker: AdvaMed's Next CEO On The Path Ahead

AdvaMed's board just selected Scott Whitaker, a top executive at the Biotechnology Innovation Organization, as the trade group's next CEO. Before he starts in the new role on April 4, he spoke with The Gray Sheet about his vision.

FDA, Industry Agree On Working Groups To Support User-Fee Negotiations

The agency and industry agreed to create working groups allowing subject-matter experts to delve deeper into technical details on some of the key proposals raised thus far in user-fee reauthorization talks. Areas of focus include de novo reviews, pre-submissions and personnel recruitment challenges.

Senate Will Tackle Separate Device Reform Bills As Part Of Innovation Agenda

Multiple bills focused on accelerating the path to market for devices will join safety legislation reforming the regulation of duodenoscopes in a slate of Senate bills that HELP Committee Chairman Lamar Alexander said will receive hearings in February, March and April. The legislation-by-legislation approach in the Senate differs from the broad-based 21st Century Cures package that advanced in the House.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts